Filing Details

Accession Number:
0001640455-22-000011
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-01-11 20:57:47
Reporting Period:
2022-01-07
Accepted Time:
2022-01-11 20:57:47
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1640455 Jounce Therapeutics Inc. JNCE Biological Products, (No Disgnostic Substances) (2836) 454870634
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1693456 Elizabeth Trehu C/O Jounce Therapeutics, Inc.
780 Memorial Drive
Cambridge MA 02139
Chief Medical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2022-01-07 3,005 $7.30 90,580 No 4 S Direct
Common Stock Disposition 2022-01-10 5,378 $6.65 85,202 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
Footnotes
  1. Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes.
  2. Represents the weighted average share price of an aggregate total of 3,005 shares sold in the price range of $7.03 to $7.65 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
  3. Represents the weighted average share price of an aggregate total of 5,378 shares sold in the price range of $6.57 to $6.90 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.